The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review.
| Autor: | Jegede O; From the Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven CT (OJ, JPDA, CH, EC, IP, SBM); and Cushing/John Hay Whitney Medical Library, Yale University School of Medicine (MCF)., De Aquino JP, Hsaio C, Caldwell E, Funaro MC, Petrakis I, Muvvala SB |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of addiction medicine [J Addict Med] 2024 Sep-Oct 01; Vol. 18 (5), pp. 499-510. Date of Electronic Publication: 2024 Aug 10. |
| DOI: | 10.1097/ADM.0000000000001356 |
| Abstrakt: | Background: The clinical implications of high potency synthetic opioids (HPSO) on medications for opioid use disorder (MOUDs) are not well understood. Although pharmacological interactions are plausible, the clinical significance of such interaction has not been systematically elucidated. This scoping review investigates the relationship between HPSO exposure and various MOUD treatment outcomes. Methods: We followed PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews) for scoping reviews with extensive a priori search strategy of databases: MEDLINE, EMBASE, PsycINFO, Web of Science, CINAHL, and Cochrane. Results: From 9149 studies, 34 fulfilled the inclusion criteria. Synthesized data reveal several critical insights: First, there is a variable but high occurrence (38%-80%) of HPSO usage among individuals with MOUDs. Second, MOUDs are linked to a decreased risk of overdoses and deaths associated with HPSO. Third, HPSO consumption is correlated with the risk of precipitated withdrawal when starting buprenorphine. Fourth, low-dose buprenorphine is being recognized as one method to avoid moderate withdrawal symptoms prior to treatment. Lastly, significant gaps exist in human experimental data concerning the effects of HPSO on key factors critical for treating OUD-craving, withdrawal symptoms, and pain. Conclusions: Current evidence supports MOUD safety and effectiveness in reducing nonmedical opioid use. Further research is needed to explore HPSO's influence on the acute factors preceding nonmedical opioid use, such as cravings, withdrawal symptoms, and pain. This research could inform the optimization of MOUD dosing strategies. Achieving consensus and harmonizing data across clinical and research protocols could diminish variability, enhancing our understanding of HPSOs effect on MOUD treatment outcomes. Competing Interests: J.P.D. is supported by grants K23DA052682, R21DA057240, and R01DA060066 from the National Institute on Drug Abuse. J.P.D. has been supported in clinical trials by Jazz Pharmaceuticals, specifically through medication provisions. Additionally, J.P.D. has been a compensated consultant for Boehringer Ingelheim. S.B.M. reported consulting for Alkermes previously. I.P. reports the following: in kind (medications) support for research studies from Alkermes and BioXcel Therapeutics; coeditor for Journal of Addiction Medicine; has received textbook royalties from McGraw/Hill; Patents and Inventions: (1) Arias A, Petrakis I, Krystal JH. Composition and methods to treat addiction. Provisional Use Patent application no. 61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research, (2) Gihyun, Yoon, Petrakis I, Krystal JH. Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. US Provisional Patent application no. 62/444,552, filed on January10, 2017, by Yale University Office of Cooperative Research OCR 7088 US01. O.J., C.H., E.C., and M.C.F. report no conflicts of interest. (Copyright © 2024 American Society of Addiction Medicine.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|